Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label, comparative, randomized, multicenter, study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients.

Trial Profile

Open label, comparative, randomized, multicenter, study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2012

At a glance

  • Drugs Docetaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms HERTAX
  • Most Recent Events

    • 08 May 2012 Additional lead trial centers identified as reported by Netherlands Trial Register.
    • 08 May 2012 Additional trial location added as reported by Netherlands Trial Register.
    • 08 May 2012 New source identified and integrated (NTR308: Netherlands Trial Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top